

NPRA Approval for Novugen Products | August 2023

Novugen

National Pharmaceutical Regulatory Agency (NPRA)

APPROVAL FOR NOVUGEN PRODUCTS

Novugen Oncology
GENESSA 250mg
 Gefitinib
 Film Coated Tablets

Advanced or Metastatic Non-small Cell Lung Cancer

1st in-house product from Novugen Oncology, approved by NPRA

Novugen Pharma
DYCOX 40mg
 Parecoxib Sodium
 Powder for solution for injection

Pain Management, Concomitant Use with Opioid Analgesics

Novugen Pharma
VOZAN 10mg / 20mg
 Vonoprazan Fumarate
 Film Coated Tablets

Gastric Ulcer, Duodenal Ulcer, Reflux Esophagitis

Novugen
 ACCELERATING AFFORDABLE MEDICINE

We are thrilled to announce that Novugen’s Genessa 250mg (Gefitinib), Dycox 40mg (Parecoxib Sodium), and Vozan 10mg / 20mg (Vonoprazan Fumarate) were recently approved by National Pharmaceutical Regulatory Agency (NPRA), last week on the 3rd of August 2023.

It is also with great pleasure that we inform you that **Genessa 250m Film Coated Tablets** is our very **First in-house product** from Novugen Oncology to receive the accreditation from the local regulatory body.

The approvals for 3 of our products marked yet another significant milestone for Novugen, a testament to our dedication to accelerate the accessibility of high-quality drugs for patients, locally.